Xtandi (enzalutamide) – advanced androgen receptor inhibitor for prostate cancer
Understanding xtandi and its role in prostate cancer treatment
Xtandi is the brand name for Enzalutamide which is an oral androgen receptor signaling inhibitor that has been developed for the treatment of prostate cancer a disease that is driven by the androgen receptor signaling pathway. Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and the androgen receptor is important in the development and progression of this disease. Even after androgen deprivation therapy which is the mainstay of initial treatment for advanced prostate cancer the androgen receptor remains active through various mechanisms including intratumoral androgen synthesis androgen receptor amplification and constitutively active androgen receptor splice variants. Xtandi was designed to more potently inhibit the androgen receptor pathway by targeting multiple steps in androgen receptor signaling and it has been shown to improve survival in men with metastatic castration-resistant prostate cancer.
The development of Xtandi built on the scientific understanding of persistent androgen receptor signaling as a key driver of castration-resistant prostate cancer. First-generation antiandrogens such as bicalutamide were limited by their relatively low affinity for the androgen receptor and by their partial agonist activity which could actually stimulate androgen receptor signaling under certain conditions. The discovery that more potent and pure androgen receptor antagonists could overcome these limitations led to the development of Enzalutamide which binds to the androgen receptor with higher affinity than first-generation agents and lacks agonist activity. The enhanced potency and purity of androgen receptor antagonism achieved with Xtandi translated into significant clinical benefits including prolonged survival delayed disease progression and improved quality of life in men with advanced prostate cancer.
Xtandi has been approved for multiple indications within the prostate cancer treatment spectrum reflecting its broad activity across different disease states. The medication is approved for the treatment of men with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy and those who are chemotherapy-naive. It is also approved for men with non-metastatic castration-resistant prostate cancer which is a disease state characterized by a rising prostate-specific antigen level despite castrate levels of testosterone in the absence of detectable metastases on conventional imaging. Additionally Xtandi has been approved for the treatment of metastatic hormone-sensitive prostate cancer in combination with androgen deprivation therapy. The expansion of Xtandi use across these different clinical settings reflects central importance of the androgen receptor pathway throughout the natural history of prostate cancer.
Mechanism of action and pharmacological properties
Xtandi exerts its anticancer effects through multiple mechanisms that target the androgen receptor signaling pathway at several distinct steps. The primary mechanism of action is competitive inhibition of androgen binding to the androgen receptor. Enzalutamide binds to the androgen receptor ligand-binding domain with an affinity that is five to eight times greater than that of bicalutamide thereby more effectively preventing the endogenous androgens testosterone and dihydrotestosterone from binding to and activating the receptor. Unlike first-generation antiandrogens Enzalutamide does not exhibit partial agonist activity when the androgen receptor is overexpressed meaning that it does not stimulate androgen receptor signaling even under conditions of androgen receptor amplification which is a common resistance mechanism in castration-resistant prostate cancer.
In addition to competitively inhibiting ligand binding Xtandi inhibits the nuclear translocation of the androgen receptor which is a critical step in the activation of androgen receptor signaling. After an androgen binds to the androgen receptor in the cytoplasm the receptor-ligand complex undergoes a conformational change that exposes a nuclear localization signal allowing the complex to be transported from the cytoplasm into the nucleus. Once inside the nucleus the androgen receptor binds to specific DNA sequences known as androgen response elements in the promoter regions of target genes and recruits coactivator proteins to initiate gene transcription. Enzalutamide induces a conformational change in the androgen receptor that impairs nuclear translocation thereby reducing the amount of androgen receptor that reaches the nucleus and can activate gene transcription.
Xtandi also inhibits the binding of the androgen receptor to DNA and the recruitment of coactivator proteins which are essential for the transcriptional activity of the receptor. Even if some androgen receptor molecules can translocate to the nucleus Enzalutamide impairs their ability to bind to androgen response elements and to recruit the coactivator proteins that are necessary for the initiation of gene transcription. This triple mechanism of action targeting ligand binding nuclear translocation and DNA binding and coactivator recruitment provides potent and comprehensive inhibition of the androgen receptor signaling pathway. The net result of these effects is the inhibition of the expression of androgen-responsive genes that drive prostate cancer cell growth and survival leading to the induction of apoptosis and the inhibition of tumor growth. The comprehensive inhibition of androgen receptor signaling achieved with Xtandi distinguishes it from earlier-generation antiandrogens and accounts for its clinical activity in patients with castration-resistant prostate cancer.
Clinical indications and evidence supporting use
Xtandi is indicated for the treatment of men with metastatic castration-resistant prostate cancer who have previously received docetaxel chemotherapy. The approval for this indication was based on the results of the AFFIRM trial which was a randomized placebo-controlled phase three study that demonstrated a significant improvement in overall survival with Enzalutamide compared to placebo in men with metastatic castration-resistant prostate cancer who had progressed after docetaxel-based chemotherapy. The median overall survival was eighteen point four months in the Enzalutamide group compared to thirteen point six months in the placebo group representing a thirty-seven percent reduction in the risk of death. The study also demonstrated significant improvements in secondary endpoints including radiographic progression-free survival time to prostate-specific antigen progression and quality of life measures providing robust evidence of the clinical benefit of Xtandi in this patient population.
Xtandi is also approved for the treatment of men with metastatic castration-resistant prostate cancer who have not previously received chemotherapy. This approval was based on the results of the PREVAIL trial which demonstrated that Enzalutamide improved overall survival and radiographic progression-free survival compared to placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer. The study showed an eighty-one percent reduction in the risk of radiographic progression or death and a twenty-nine percent reduction in the risk of death with Enzalutamide treatment. These results established Xtandi as a standard treatment option for men with metastatic castration-resistant prostate cancer regardless of prior chemotherapy exposure and expanded the population of patients who could benefit from this therapy.
Additional approved indications for Xtandi include the treatment of men with non-metastatic castration-resistant prostate cancer based on the results of the PROSPER trial and the treatment of men with metastatic hormone-sensitive prostate cancer based on the results of the ARCHES and ENZAMET trials. In non-metastatic castration-resistant prostate cancer Xtandi delayed the development of metastases and prolonged overall survival providing a meaningful clinical benefit for men with this disease stage. In metastatic hormone-sensitive prostate cancer the addition of Xtandi to androgen deprivation therapy improved radiographic progression-free survival and overall survival establishing a role for potent androgen receptor inhibition earlier in the disease course. The expansion of Xtandi use across these different clinical settings reflects broad activity of the medication and the importance of the androgen receptor pathway throughout the natural history of prostate cancer.
Dosing schedules and administration guidelines
The recommended dose of Xtandi is one hundred sixty milligrams which is administered orally as four forty-milligram capsules taken together once daily. The capsules should be swallowed whole with a glass of water and can be taken with or without food. Consistent daily dosing at approximately the same time each day is recommended to maintain stable drug levels and to establish a routine that promotes adherence. Patients should be advised not to crush chew or open the capsules because this could alter the absorption of the medication and could potentially expose others to the drug through skin contact with the capsule contents. If a patient has difficulty swallowing the capsules whole they should discuss alternative strategies with their healthcare provider.
Xtandi can be taken with or without food but patients should be advised to avoid taking the medication with grapefruit or grapefruit juice because grapefruit can inhibit cytochrome P450 three A four an enzyme that is involved in the metabolism of Enzalutamide and can potentially increase drug exposure. If a dose of Xtandi is missed and the patient remembers within several hours of the scheduled dosing time the missed dose should be taken immediately and the next dose should be taken at the regular time the following day. If the patient does not remember until the next day the missed dose should be skipped and the regular dosing schedule should be resumed. Patients should be advised not to double the dose to make up for a missed dose because this could increase the risk of adverse effects without providing additional therapeutic benefit.
Dose modifications may be necessary for patients who experience adverse effects during treatment with Xtandi particularly fatigue and other central nervous system effects. For patients who experience intolerable toxicity the dose may be reduced to one hundred twenty milligrams once daily which is administered as three forty-milligram capsules taken together or to eighty milligrams once daily which is administered as two forty-milligram capsules taken together. The dose should be reduced in a stepwise manner based on the severity of the toxicity and the patient’s ability to tolerate the medication. If toxicity resolves or improves with dose reduction the dose may be subsequently increased if clinically appropriate and if the patient is tolerating the lower dose well. The decision to modify the dose should be made by the treating healthcare provider based on a careful assessment of the risk-benefit balance for the individual patient.
Safety profile and management of adverse effects
The safety profile of Xtandi has been characterized through extensive clinical trial experience with thousands of patients treated across multiple disease settings. The most common adverse effects include fatigue asthenia or weakness hot flashes hypertension headache and musculoskeletal pain including back pain and arthralgia. Fatigue and asthenia are among the most frequently reported adverse effects and can be significant for some patients. These symptoms are thought to be related to the central nervous system effects of Enzalutamide which can cross the blood-brain barrier and may affect the function of gamma-aminobutyric acid type A receptors. The management of fatigue includes lifestyle modifications such as maintaining a regular sleep schedule engaging in appropriate physical activity and conserving energy for important activities. In some cases dose reduction may be necessary to manage persistent or severe fatigue.
Seizures are a potentially serious adverse effect that has been associated with Xtandi and the medication carries a warning about the risk of seizure. The mechanism of seizure risk is thought to be related to the off-target inhibitory effect of Enzalutamide on gamma-aminobutyric acid type A receptors in the central nervous system. The incidence of seizures in clinical trials was low at less than one percent but any seizure in a patient taking Xtandi should be evaluated promptly. Xtandi should be used with caution in patients with a history of seizures or with conditions that predispose to seizures including brain metastases cerebrovascular disease and the use of medications that lower the seizure threshold. Patients should be advised not to engage in activities where a sudden loss of consciousness could cause serious harm to themselves or others if they experience a seizure warning sign or event.
Hypertension is a common adverse effect of Xtandi and blood pressure should be monitored at baseline and periodically during treatment. New or worsening hypertension should be managed according to established guidelines with lifestyle modifications and antihypertensive medications as needed. Other cardiovascular effects including ischemic heart disease have been reported in patients receiving Xtandi and patients with pre-existing cardiovascular disease should be monitored for worsening of their condition. Falls and fractures have been reported more frequently in patients receiving Xtandi compared to placebo in some clinical trials and the risk appears to be related in part to the central nervous system effects of the medication. Patients at risk for falls including elderly patients and those with impaired mobility should be monitored and appropriate fall prevention strategies should be implemented.
Buy Xtandi (Enzalutamide) Over The Counter at Happy Family Pharmacy
Drug interactions and concomitant medication management
Xtandi is both a substrate for and an inducer of several cytochrome P450 enzymes which creates the potential for bidirectional drug interactions with many medications. Enzalutamide is a strong inducer of cytochrome P450 three A four a moderate inducer of cytochrome P450 two C nine and cytochrome P450 two C nineteen and a weak inducer of cytochrome P450 two B six. As an inducer of these enzymes Xtandi can accelerate the metabolism of other drugs that are substrates for the same enzymes potentially reducing their plasma concentrations and therapeutic effectiveness. Medications that may have reduced efficacy when co-administered with Xtandi include certain anticoagulants such as warfarin anticonvulsants antidepressants immunosuppressants and many other drugs. A thorough medication review should be conducted before initiating Xtandi and before starting any new medications during therapy.
The interaction between Xtandi and warfarin and other coumarin anticoagulants is particularly important because a reduction in anticoagulant effect could increase the risk of thromboembolic events. The international normalized ratio should be monitored more frequently in patients receiving warfarin and Xtandi and the warfarin dose may need to be adjusted to maintain adequate anticoagulation. Direct oral anticoagulants that are metabolized by cytochrome P450 three A four may also have reduced efficacy when co-administered with Xtandi and alternative anticoagulants that are not metabolized by this enzyme may be preferred. Patients should be advised to report any signs or symptoms of thromboembolism or bleeding to their healthcare provider and to have their coagulation parameters monitored as recommended.
Xtandi can interact with medications that are strong inhibitors or inducers of cytochrome P450 enzymes affecting Enzalutamide exposure and potentially influencing its safety and efficacy. Strong inhibitors of cytochrome P450 three A four such as ketoconazole and clarithromycin can increase Enzalutamide exposure and may increase the risk of adverse effects. Conversely strong inducers of cytochrome P450 two C eight and cytochrome P450 three A four such as rifampicin can decrease Enzalutamide exposure and may reduce its therapeutic efficacy. The co-administration of Xtandi with strong enzyme inducers should be avoided when possible and alternative medications that do not affect drug metabolism should be used. If co-administration with a strong enzyme inducer is unavoidable the patient should be monitored closely for signs of reduced efficacy and the dose of Xtandi may need to be adjusted.
Special populations and treatment considerations
Elderly patients represent the majority of men with prostate cancer and understanding the use of Xtandi in this population is of particular importance. In clinical trials no overall differences in the safety or efficacy of Xtandi were observed between elderly patients aged sixty-five and older and younger patients. However greater sensitivity to the central nervous system effects of the medication particularly fatigue and an increased risk of falls cannot be excluded in older patients. Geriatric patients should be monitored more closely for adverse effects and dose reduction should be considered in those who experience significant toxicity. The management of elderly patients with advanced prostate cancer should take into account their overall health status functional status comorbidities and treatment goals. The use of a comprehensive geriatric assessment can help identify patients who are at increased risk of treatment-related complications.
Patients with hepatic impairment have altered metabolism of Enzalutamide and dose adjustments may be necessary based on the severity of liver dysfunction. In patients with mild hepatic impairment Child-Pugh class A no dose adjustment of Xtandi is required because the increase in Enzalutamide exposure is modest and is considered clinically acceptable. In patients with moderate hepatic impairment Child-Pugh class B the exposure to Enzalutamide is increased and the recommended dose is reduced to eighty milligrams once daily. In patients with severe hepatic impairment Child-Pugh class C Xtandi has not been studied and is not recommended because the potential for excessive drug exposure and toxicity is a concern. Liver function should be assessed before starting Xtandi and periodically during treatment.
Patients with renal impairment including those with mild moderate or severe renal impairment can receive the standard dose of Xtandi without adjustment because renal excretion is not a major route of elimination for Enzalutamide. However patients with end-stage renal disease have not been specifically studied and the effects of hemodialysis on Enzalutamide pharmacokinetics are not known. Xtandi should be used with caution in patients with severe renal impairment and clinical monitoring for adverse effects should be conducted. Patients with prostate cancer may have urinary tract obstruction and renal dysfunction as a result of their disease and the management of these issues should be integrated with the management of their cancer therapy.
Patient education and quality of life considerations
Patient education is an essential component of safe and effective treatment with Xtandi. Patients should receive detailed information about the purpose of the medication how it works and what to expect during treatment. They should be educated about the potential adverse effects including fatigue hot flashes hypertension and the rare but serious risk of seizures. Patients should be advised to report any new or worsening symptoms to their healthcare provider including unusual tiredness and weakness swelling in the ankles or legs and any symptoms that could suggest a seizure such as confusion unusual sensations or loss of consciousness. The importance of adherence to the prescribed dosing schedule should be emphasized and patients should be counseled about what to do if they miss a dose.
Xtandi can have effects on reproductive function and male fertility and patients should be counseled about these potential effects before starting treatment. Enzalutamide can impair spermatogenesis and may reduce male fertility. The medication can also reduce libido due to its potent inhibition of androgen receptor signaling throughout the body. Patients who wish to preserve their fertility should discuss options such as sperm banking before starting treatment. Xtandi can cause harm to a developing fetus and male patients with female partners of reproductive potential should use effective contraception during treatment and for at least three months after the last dose. The contraceptive requirements should be discussed with patients and their partners and appropriate contraceptive methods should be implemented.
Quality of life is an important consideration in the treatment of advanced prostate cancer and Xtandi has been shown to improve or maintain quality of life in several clinical trials. The delay in disease progression and the palliation of cancer-related symptoms can contribute to improved physical emotional and social well-being. However treatment-related adverse effects can negatively impact quality of life and should be proactively managed. The integration of palliative and supportive care services into the management of patients with advanced prostate cancer can help address symptom burden provide psychosocial and spiritual support and improve overall quality of life. Patients should be encouraged to communicate openly with their healthcare team about their symptoms concerns and treatment goals so that therapy can be tailored to optimize both disease control and quality of life.
Resistance mechanisms and future directions in prostate cancer therapy
Despite the significant benefits provided by Xtandi and other potent androgen receptor signaling inhibitors resistance to these agents eventually develops in most patients with advanced prostate cancer. Several mechanisms of resistance have been identified including the emergence of androgen receptor splice variants particularly the androgen receptor variant seven which lacks the ligand-binding domain but remains constitutively active. Because this variant does not require ligand binding for activation it is not inhibited by Enzalutamide or other agents that target the ligand-binding domain. Other resistance mechanisms include androgen receptor point mutations that alter drug binding or convert antagonists to agonists amplification of the androgen receptor gene activation of alternative signaling pathways such as the glucocorticoid receptor pathway and neuroendocrine differentiation which allows prostate cancer cells to survive and proliferate independently of androgen receptor signaling.
Practical management of fatigue and quality of life
Fatigue is one of the most common adverse effects experienced by patients taking Xtandi and its impact on quality of life can be substantial. The management of fatigue requires a comprehensive approach that includes non-pharmacological strategies such as energy conservation techniques scheduled periods of rest and activity and the maintenance of physical activity within the limits of tolerance. Exercise programs tailored to the individual patient’s capabilities including aerobic training and resistance exercise have been shown to improve fatigue and quality of life in patients with advanced prostate cancer. Nutritional support to maintain adequate caloric intake and prevent weight loss is important because malnutrition can exacerbate fatigue. The correction of contributing factors such as anemia pain sleep disturbances and depression should also be addressed. In some cases dose reduction of Xtandi may be necessary to manage persistent or severe fatigue that does not respond to conservative measures.
The importance of multidisciplinary care in prostate cancer
The optimal management of advanced prostate cancer requires a multidisciplinary approach that integrates the expertise of medical oncologists radiation oncologists urologists palliative care specialists and other healthcare professionals. Medical oncologists primarily manage systemic therapy with Xtandi and other agents but radiation oncologists play a critical role for bone metastases and other sites of symptomatic disease. Urologists address local complications of prostate cancer including urinary obstruction and hematuria. Palliative care specialists provide expertise in symptom management psychosocial support and advance care planning and their involvement early in the disease course is associated with improved quality of life and patient satisfaction. The coordination of care among these various specialists is essential for ensuring that all aspects of the patient’s health are addressed and that treatment decisions are made collaboratively with the patient and their family.
Resistance mechanisms and future directions in prostate cancer therapy
Despite the significant benefits provided by Xtandi and other potent androgen receptor signaling inhibitors resistance to these agents eventually develops in most patients with advanced prostate cancer. Several mechanisms of resistance have been identified including the emergence of androgen receptor splice variants particularly the androgen receptor variant seven which lacks the ligand-binding domain but remains constitutively active. Because this variant does not require ligand binding for activation it is not inhibited by Enzalutamide or other agents that target the ligand-binding domain. Other resistance mechanisms include androgen receptor point mutations that alter drug binding or convert antagonists to agonists amplification of the androgen receptor gene activation of alternative signaling pathways such as the glucocorticoid receptor pathway and neuroendocrine differentiation which allows prostate cancer cells to survive and proliferate independently of androgen receptor signaling.
The emergence of resistance to Xtandi and other androgen receptor inhibitors has prompted research into new therapeutic strategies that can overcome or circumvent these resistance mechanisms. Novel agents are being developed that target the androgen receptor through different mechanisms including androgen receptor degraders that promote the proteasomal degradation of the receptor rather than simply inhibiting its activity and agents that target the amino-terminal domain of the receptor which is retained in splice variants that lack the ligand-binding domain. Combination strategies are being explored in which Xtandi is combined with other targeted agents such as PARP inhibitors which target DNA repair pathways that are particularly important in prostate cancers with mutations in DNA repair genes and with immunotherapy agents that aim to harness the immune system to recognize and eliminate cancer cells. Sequencing strategies that rationally order available therapies based on the mechanisms of resistance that emerge during treatment may also help to maximize the duration of disease control.
The continued refinement of prostate cancer treatment will depend on a deeper understanding of the biology of the disease and the development of biomarkers that can guide treatment selection. Liquid biopsies that detect circulating tumor cells cell-free tumor DNA and androgen receptor splice variants in the blood hold promise for monitoring treatment response and detecting the emergence of resistance in real time. Molecular imaging using prostate-specific membrane antigen targeted positron emission tomography can detect sites of disease that are not visible on conventional imaging and may allow for more precise staging and earlier detection of disease progression. The integration of these advanced diagnostic tools with an expanding options of therapeutic agents should lead to further improvements in outcomes for men with advanced prostate cancer and the ultimate goal of transforming this disease from a fatal illness into a manageable chronic condition.